IDYA IDEAYA Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1676725 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.1%
TTM net income YoY-143.0%
TTM EPS YoY-71.4%
Revenue 3-yr CAGR-37.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,671.1%
Net margin-3,921.1%
FCF margin-3,592.0%
EBITDA margin-4,637.0%
Returns
ROE-32.7%
ROA-31.0%
ROIC (approx.)-35.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.8%
Debt / equity0.00x
Current ratio14.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue55.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $218.71M | $7.00M |
| R&D expense | $314.70M | $294.67M |
| SG&A expense | $63.32M | $39.30M |
| Operating income | -$159.31M | -$326.98M |
| Income tax | $0 | $0 |
| Net income | -$113.70M | -$274.48M |
| EBITDA | -$156.61M | -$324.59M |
| EPS (basic) | -1.28 | -3.36 |
| EPS (diluted) | -1.28 | -3.36 |
| Weighted avg. shares (diluted) | 88.49M | 81.68M |
| Balance sheet | ||
| Cash & equivalents | $112.83M | $85.18M |
| Short-term investments | $526.56M | $591.94M |
| Receivables | — | $3,000 |
| Current assets | $666.73M | $689.71M |
| PP&E, net | $8.22M | $8.97M |
| Total assets | $1.11B | $1.12B |
| Current liabilities | $58.81M | $46.07M |
| Total liabilities | $86.39M | $64.94M |
| Shareholders' equity | $1.02B | $1.06B |
| Shares outstanding | 87.80M | 86.50M |
| Cash flow statement | ||
| Operating cash flow | -$71.10M | -$247.58M |
| Capital expenditure | $2.37M | $3.86M |
| Free cash flow | -$73.47M | -$251.44M |
| Investing cash flow | $69.98M | -$502.56M |
| Financing cash flow | $29.78M | $677.55M |
| Depreciation & amortization | $2.70M | $2.39M |
| Stock-based compensation | $46.12M | $34.75M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.